Results for tag: "Lorlatinib"

Lorlatinib is a type of lung cancer drug used to treat non-small cell lung cancer (NSCLC). It is a kinase inhibitor, meaning it works by blocking certain proteins that help cancer cells grow and divide. It is used to treat patients with ALK-positive NSCLC who have progressed after treatment with crizotinib. Lorlatinib is taken orally, usually once a day. Common side effects include fatigue, nausea, diarrhea, and rash. Lorlatinib is a relatively new drug, approved by the US Food and Drug Administration (FDA) in 2018. It is the first ALK inhibitor to be approved for the treatment of ALK-positive NSCLC. It is also the first drug to be approved for the treatment of brain metastases in ALK-positive NSCLC. The lorlatinib market is growing rapidly, as it is an effective treatment for ALK-positive NSCLC. It is expected to be a major player in the lung cancer drug market in the coming years. Some companies in the lorlatinib market include Pfizer, Merck, and AstraZeneca. Show Less Read more